Human Nanog Differentiation Reporter (pGreenZeo, pre_packaged)
- Known as:
- Human Nanog Differentiation Reporter (pGreenZeo, pre_packaged)
- Catalog number:
- SR10030VA-1
- Product Quantity:
- >2 x 10^6 IFUs
- Category:
- -
- Supplier:
- SBI
- Gene target:
- Human Nanog Differentiation Reporter (pGreenZeo pre_packaged)
Related genes to: Human Nanog Differentiation Reporter (pGreenZeo, pre_packaged)
- Gene:
- NANOG NIH gene
- Name:
- Nanog homeobox
- Previous symbol:
- -
- Synonyms:
- FLJ12581, FLJ40451
- Chromosome:
- 12p13.31
- Locus Type:
- gene with protein product
- Date approved:
- 2003-09-10
- Date modifiied:
- 2014-11-19
Related products to: Human Nanog Differentiation Reporter (pGreenZeo, pre_packaged)
Related articles to: Human Nanog Differentiation Reporter (pGreenZeo, pre_packaged)
- - Source: PubMed
Publication date: 2026/09/07
Chen Chia-LinUthaya Kumar Dinesh BabuPunj VasuXu JunSher LindaTahara Stanley MHess SonjaMachida Keigo - For the first time, this study aimed to investigate the potential protective effects of L-carnitine and moderate-intensity exercise training (MIET), both individually and in combination, against varicocele (VCL)-induced impairment of spermatogonial stem cell (SSC) self-renewal. - Source: PubMed
Publication date: 2026/08/08
Ibrahim Abdulameer Al-Khuzaie ZainabTolouei Azar JavadNasr-Esfahani Mohammad HosseinRazi Mazdak - Cancer-associated fibroblasts (CAFs) contribute to pancreatic cancer (PC) progression and therapeutic resistance. This study investigated whether CAF-derived exosomes (CAF-exo)-promote PC cell stemness and gemcitabine (GEM) resistance by delivering Snail and regulating the suppressor of cytokine signaling 6/hypoxia-inducible factor-1α (SOCS6/HIF-1α) axis. - Source: PubMed
Publication date: 2026/09/05
Luo ZhenHu YuqinLi JianXu DayongXu JinLi HaoZou Fang - Seminoma, which is the most frequent testicular germ cell tumor, has stem cell-like features related to treatment resistance and recurrence, yet the molecular mechanisms that preserve its stemness are not well understood. This study aimed to discover the tumorigenesis and stemness regulation of seminoma. In vivo CRISPR/Cas9 knockout library screening was performed using Tcam-2 seminoma cells implanted into NSG mice to identify tumorigenesis drivers. Parallel FACS-based screening enriched CD117/CD133 double-negative cells to assess the regulators of seminoma stemness. Functional validation included clonogenicity assays, sphere formation tests, and tumor initiation experiments in vivo. RNA sequencing analyzed downstream pathways. In vivo and FACS-based CRISPR/Cas9 screening uncovers VENTX as a crucial element in maintaining seminoma stemness. Functional validation showed that VENTX knockout decreased clonogenicity, sphere formation, and CD117+/CD133+ populations in Tcam-2 cells, and also hindered tumor initiation in vivo. RNA sequencing identified a connection between VENTX and pluripotency pathways, demonstrating a downregulation of ID1/2/3 (essential differentiation inhibitors) and an imbalance in Wnt/β-catenin and TGF-β signaling. VENTX expression showed a significant association with DNA methylation-based stemness scores in testicular germ cell tumors. In conclusion, VENTX is a key regulator of seminoma stemness, presenting a promising target for therapy to address recurrence and resistance in seminoma. - Source: PubMed
Publication date: 2026/09/03
Huang ChaoxiongChen YiranZhang EnhuanWang YifanLiu YixuanTang LiruiChen ChuanbenLin PeichengWang Bingyi - Lung cancer remains the leading cause of cancer-related mortality worldwide, largely due to therapeutic resistance and tumor recurrence. In non-small cell lung cancer (NSCLC), cancer stem cells (CSCs) have emerged as key contributors to tumor persistence and progression. However, accelerated CSC-targeted drug discovery is limited by the lack of scalable and quantitative screening systems capable of capturing stemness-associated phenotypes. Conventional two-dimensional (2D) assays often fail to reflect the architectural and molecular complexity of CSC-enriched tumor populations. Here, we report the establishment of a luciferase-based three-dimensional (3D) NSCLC spheroid platform integrating CSC-like enrichment with a high-throughput quantitative readout. The luminescent signal strongly correlated with spheroid burden and viable cell content. Compared with 2D monolayers, 3D NSCLC spheroids exhibited elevated expression of pluripotency-associated factors, including OCT4, NANOG, and SOX2, and CSC-associated markers, namely CD44, ALDH1A1, and ABCG2, supporting the enrichment of CSC-like subpopulations. As a proof-of-concept, screening of renieramycin T right-half derivatives identified DH_18 as a lead compound in the established 3D NSCLC spheroid model, exhibiting greater potency than DH_19, accompanied by increased apoptosis and reduced CSC-associated proteins in follow-up experimental validation. Integrated network pharmacology incorporating enrichment and protein-protein interaction analyses further mapped DH_18-NSCLC targets to lung CSC-associated networks and pathways related to stemness and aggressive tumor phenotypes, reinforcing the biological relevance of the 3D screening context. Collectively, these findings present a quantitative and scalable 3D NSCLC spheroid platform suitable for CSC-targeted drug screening and nominate DH_18 as a candidate compound with potential activity against stemness-linked molecular networks. - Source: PubMed
Publication date: 2026/09/01
Samart ParinyaChanthateyanonth SupasornRodboon NapachaiCharoenvitayavorakul NititYamada TatsukiYokoya MasashiChanvorachote PithiIssaragrisil SurapolLuanpitpong Sudjit